// App-Quantinova.ai

2584 : Final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers.

Researchers

Presenter

  • Kim Anna Reiss

Principal Investigators

  • Joseph M. Herman

  • Marianna Zahurak

  • Anthony W. Fyles

  • Michael F. Milosevic

  • Angela Scardina

  • Caitlin Joffe

  • Emily Petito

  • Amy Hacker-Prietz

  • Alice P. Chen

  • Sarah Madhu Temkin

  • Naomi Horiba

  • Robert J. Kinders

  • Lihua Wang

  • Lee-Anne Stayner

  • Nilofer Saba Azad

Medical Centers

  • Johns Hopkins University, Baltimore, MD

  • Johns Hopkins University School of Medicine, Baltimore, MD

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Princess Margaret Hospital, Toronto, ON, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Johns Hopkins University School of Medicine, Baltimore, MD

  • Early Clinical Trials Development Program, DCTD, National Cancer Institute at the National Institutes of Health, Bethesda, MD

  • National Cancer Institute, Rockville, MD

  • University of Maryland, Baltimore, MD

  • Leidos-Frederick, Frederick, MD

  • SAIC-Frederick, Frederick, MD

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Peritoneal carcinomatosis

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Veliparib

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT01264432

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved